This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments CI
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023
Top Premarket Gainers MT
Private Payrolls Increased Less Than Expected in November as US Equity Futures Rise Pre-Bell MT
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday MT
Top Premarket Decliners MT
ImmunoPrecise Antibodies Plans Underwritten Offering of Common Stock; Shares Fall Pre-Bell MT
ImmunoPrecise Antibodies Ltd. Announces Board Changes CI
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology CI
ImmunoPrecise Antibodies Names Kristin Taylor Interim Finance Chief MT
ImmunoPrecise Antibodies Announces CFO Transition CI
Transcript : ImmunoPrecise Antibodies Ltd., Q1 2024 Earnings Call, Sep 14, 2023
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
ImmunoPrecise Antibodies Ltd. Announces Board Changes CI
ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing CI
Transcript : ImmunoPrecise Antibodies Ltd. - Special Call
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
ImmunoPrecise Antibodies Ltd. Auditor Raises 'Going Concern' Doubt CI
Ingalls & Snyder Proposes a Change to the Members of ImmunoPrecise Antibodies’ Board CI
Chart ImmunoPrecise Antibodies Ltd.
More charts
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
More about the company
  1. Stock Market
  2. Equities
  3. IPA Stock
  4. IPA Stock
  5. News ImmunoPrecise Antibodies Ltd.
  6. ImmunoPrecise Antibodies : Dual Listed ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program in The Netherlands